Nandrolone phenylpropionate
Nandrolone phenylpropionate (NPP), or nandrolone phenpropionate, sold under the brand name Durabolin among others, is an androgen and anabolic steroid (AAS) medication which has been used primarily in the treatment of breast cancer and osteoporosis in women.[8][9][10][11][3] It is given by injection into muscle once every week.[3] Although it was widely used in the past, the drug has mostly been discontinued and hence is now mostly no longer available.[3][11]
Side effects of NPP include symptoms of masculinization like acne, increased hair growth, voice changes, and increased sexual desire.[3] The drug is a synthetic androgen and anabolic steroid and hence is an agonist of the androgen receptor (AR), the biological target of androgens like testosterone and dihydrotestosterone (DHT).[3][12] It has strong anabolic effects and weak androgenic effects, which give it a mild side effect profile and make it especially suitable for use in women and children.[3][12][13] NPP is a nandrolone ester and a long-lasting prodrug of nandrolone in the body.[3]
NPP was first described in 1957 and was introduced for medical use in 1959.[3] It was the first nandrolone ester to be introduced, followed by nandrolone decanoate in 1962, and has been one of the most widely used nandrolone esters.[3][14] However, in more recent times, the drug has been largely superseded by nandrolone decanoate, which is longer-acting and more convenient to use.[3][11] In addition to its medical use, NPP is used to improve physique and performance.[3] The drug is a controlled substance in many countries and so non-medical use is generally illicit.[3]
NPP has been used mainly in the treatment of advanced breast cancer in women and as an adjunct therapy for the treatment of senile or postmenopausal osteoporosis in women.[3] Historically, it has also had a variety of other uses.[3] Because of its reduced androgenic effects, the drug has not generally been used in androgen replacement therapy for androgen deficiency in men and has instead been used for solely for anabolic indications.[2][15] However, nandrolone esters have more recently been proposed for the treatment of androgen deficiency in men due to favorable properties including their high ratio of anabolic to androgenic effects and consequent much lower risk of prostate enlargement, prostate cancer, and scalp hair loss relative to testosterone.[16][17]
Androgen/anabolic steroid dosages for breast cancer Route Medication Form Dosage Oral Methyltestosterone Tablet 30-200 mg/day Fluoxymesterone Tablet 10-40 mg 3x/day Calusterone Tablet 40-80 mg 4x/day Normethandrone Tablet 40 mg/day Buccal Methyltestosterone Tablet 25-100 mg/day Injection (IMTooltip intramuscular injection or SCTooltip subcutaneous injection) Testosterone propionate Oil solution 50-100 mg 3x/week Testosterone enanthate Oil solution 200-400 mg 1x/2-4 weeks Testosterone cypionate Oil solution 200-400 mg 1x/2-4 weeks Mixed testosterone esters Oil solution 250 mg 1x/week Methandriol Aqueous suspension 100 mg 3x/week Androstanolone (DHT) Aqueous suspension 300 mg 3x/week Drostanolone propionate Oil solution 100 mg 1-3x/week Metenolone enanthate Oil solution 400 mg 3x/week Nandrolone decanoate Oil solution 50-100 mg 1x/1-3 weeks Nandrolone phenylpropionate Oil solution 50-100 mg/week Note: Dosages are not necessarily equivalent. Sources: See template.NPP is or has been available 25 mg/mL and 50 mg/mL formulations in oil solution for intramuscular injection.[3]
NPP is used for physique- and performance-enhancing purposes by competitive athletes, bodybuilders, and powerlifters.[3] Nandrolone esters have been said to be the most popular AAS used by bodybuilders and in sports.[3][18] This is in part due to the high ratio of anabolic to androgenic effect of nandrolone and its weak propensity for androgenic and estrogenic side effects.[3]
The most common side effects of NPP consist of virilization (masculinization) in women, including symptoms such as acne, hirsutism (increased body/facial hair growth), hoarseness of the voice, and voice deepening.[3] However, relative to most other AAS, NPP has a greatly reduced propensity for virilization and such side effects are relatively uncommon at recommended dosages.[3] At higher dosages and/or with long-term treatment they make increase in incidence and magnitude however.[3] A variety of uncommon and rare side effects may also occur.[3]
Antiestrogens like aromatase inhibitors (e.g., anastrozole) and selective estrogen receptor modulators (e.g., tamoxifen, raloxifene) can interfere with and prevent the estrogenic effects of NPP.[3] 5α-Reductase inhibitors like finasteride and dutasteride can prevent the inactivation of nandrolone in so-called "androgenic" tissues like the skin, hair follicles, and prostate gland and may therefore considerably increase its androgenic side effects.[3] This is opposite to the case of most other AAS, which are either potentiated by 5α-reductase in such tissues or are not metabolized by 5α-reductase.[3] Antiandrogens like cyproterone acetate, spironolactone, and bicalutamide can block both the anabolic and androgenic effects of NPP.[19]
NPP is a nandrolone ester, or a prodrug of nandrolone.[20][3] As such, it is an androgen and anabolic steroid, or an agonist of the androgen receptor, the biological target of androgens like testosterone.[3][20] Relative to testosterone, NPP has enhanced anabolic effects and reduced androgenic effects.[20][3] In addition to its anabolic and androgenic activity, NPP has low estrogenic activity (via its metabolite estradiol) and moderate progestogenic activity.[3] Like other AAS, NPP has antigonadotropic effects, which are due to both its androgenic and progestogenic activity.[3]
Relative affinities (%) of nandrolone and related steroids Compound PRTooltip Progesterone receptor ARTooltip Androgen receptor ERTooltip Estrogen receptor GRTooltip Glucocorticoid receptor MRTooltip Mineralocorticoid receptor SHBGTooltip Sex hormone-binding globulin CBGTooltip Corticosteroid-binding globulin Nandrolone 20 154-155 <0.1 0.5 1.6 1-16 0.1 Testosterone 1.0-1.2 100 <0.1 0.17 0.9 19-82 3-8 Estradiol 2.6 7.9 100 0.6 0.13 8.7-12 <0.1 Notes: Values are percentages (%). Reference ligands (100%) were progesterone for the PRTooltip progesterone receptor, testosterone for the ARTooltip androgen receptor, estradiol for the ERTooltip estrogen receptor, dexamethasone for the GRTooltip glucocorticoid receptor, aldosterone for the MRTooltip mineralocorticoid receptor, dihydrotestosterone for SHBGTooltip sex hormone-binding globulin, and cortisol for CBGTooltip corticosteroid-binding globulin. Sources: See template. Relative affinities of nandrolone and related steroids at the androgen receptor Compound rAR (%) hAR (%) Testosterone 38 38 5α-Dihydrotestosterone 77 100 Nandrolone 75 92 5α-Dihydronandrolone 35 50 Ethylestrenol ND 2 Norethandrolone ND 22 5α-Dihydronorethandrolone ND 14 Metribolone 100 110 Sources: See template.NPP is converted into nandrolone in the body, which is the active form of the drug.[3] It has an extended elimination half-life in the body when administered via intramuscular injection.[20] Its duration of action is approximately one week and it is administered once every few days to once per week.[3] The elimination half-life and duration of action of NPP are much shorter than those of nandrolone decanoate.[3][21]
Parenteral durations of androgens/anabolic steroids Medication Form Major brand names Duration Testosterone Aqueous suspension Andronaq, Sterotate, Virosterone 2-3 days Testosterone propionate Oil solution Androteston, Perandren, Testoviron 3-4 days Testosterone phenylpropionate Oil solution Testolent 8 days Testosterone isobutyrate Aqueous suspension Agovirin Depot, Perandren M 14 days Mixed testosterone estersa Oil solution Triolandren 10-20 days Mixed testosterone estersb Oil solution Testosid Depot 14-20 days Testosterone enanthate Oil solution Delatestryl 14-28 days Testosterone cypionate Oil solution Depovirin 14-28 days Mixed testosterone estersc Oil solution Sustanon 250 28 days Testosterone undecanoate Oil solution Aveed, Nebido 100 days Testosterone buciclated Aqueous suspension 20 Aet-1, CDB-1781e 90-120 days Nandrolone phenylpropionate Oil solution Durabolin 10 days Nandrolone decanoate Oil solution Deca Durabolin 21-28 days Methandriol Aqueous suspension Notandron, Protandren 8 days Methandriol bisenanthoyl acetate Oil solution Notandron Depot 16 days Metenolone acetate Oil solution Primobolan 3 days Metenolone enanthate Oil solution Primobolan Depot 14 days Note: All are via i.m. injection. Footnotes: a = TP, TV, and TUe. b = TP and TKL. c = TP, TPP, TiCa, and TD. d = Studied but never marketed. e = Developmental code names. Sources: See template.Nandrolone phenylpropionate, or nandrolone 17β-phenylpropionate, is a synthetic estrane steroid and a derivative of testosterone.[8][9] It is an androgen ester; specifically, it is the C17β phenylpropionate ester of nandrolone (19-nortestosterone), which itself is the 19-demethylated analogue of testosterone.[8][9]
Structural properties of major anabolic steroid esters Anabolic steroid Structure Ester Relativemol. weight RelativeAAS contentb Durationc Position Moiety Type Lengtha Boldenone undecylenate C17β Undecylenic acid Straight-chain fatty acid 11 1.58 0.63 Long Drostanolone propionate C17β Propanoic acid Straight-chain fatty acid 3 1.18 0.84 Short Metenolone acetate C17β Ethanoic acid Straight-chain fatty acid 2 1.14 0.88 Short Metenolone enanthate C17β Heptanoic acid Straight-chain fatty acid 7 1.37 0.73 Long Nandrolone decanoate C17β Decanoic acid Straight-chain fatty acid 10 1.56 0.64 Long Nandrolone phenylpropionate C17β Phenylpropanoic acid Aromatic fatty acid - (~6-7) 1.48 0.67 Long Trenbolone acetate C17β Ethanoic acid Straight-chain fatty acid 2 1.16 0.87 Short Trenbolone enanthated C17β Heptanoic acid Straight-chain fatty acid 7 1.41 0.71 Long Footnotes: a = Length of ester in carbon atoms for straight-chain fatty acids or approximate length of ester in carbon atoms for aromatic fatty acids. b = Relative androgen/anabolic steroid content by weight (i.e., relative androgenic/anabolic potency). c = Duration by intramuscular or subcutaneous injection in oil solution. d = Never marketed. Sources: See individual articles.NPP was first described in 1957 and was introduced for medical use in 1959.[3][27] It was initially used for a wide variety of indications, but starting in the 1970s its use became more restricted and its main uses became the treatment of breast cancer and osteoporosis in women.[3] Today, NPP is scarcely available.[3] The drug was the first form of nandrolone to be introduced, and was followed by nandrolone decanoate in 1962, which has been more widely used in comparison.[27]
Nandrolone phenylpropionate is the generic name of the drug and its BANTooltip British Approved Name while nandrolone phenpropionate is its USANTooltip United States Adopted Name.[8][9][10][11] It has also been referred to as nandrolone phenylpropanoate or as nandrolone hydrocinnamate.[8][9][10][11]
NPP is or has been marketed under a variety of brand names including Durabolin, Fenobolin, Activin, Deca-Durabolin, Evabolin, Grothic, Hybolin Improved, Metabol, Nerobolil, Neurabol, Norabol, Noralone, Sintabolin, Strabolene, and Superanabolon.[8][9][10][11]
NPP is or has been marketed in many countries throughout the world, including in the United States, the United Kingdom, and Canada.[9][11]
NPP was marketed previously in the United States but is no longer available in this country.[28] Nandrolone decanoate, conversely, is one of the few AAS that remains available for medical use in this country.[28]
NPP, along with other AAS, is a schedule III controlled substance in the United States under the Controlled Substances Act.[29]
Link nội dung: https://mcbs.edu.vn/phenyl-propionat-a33919.html